Onchocerciasis Treatment Market Forecast Highlights Expansion From $1.19 Billion To $1.59 Billion Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Onchocerciasis Treatment Market Expansion From $1.19 Billion In 2026 To $1.59 Billion In 2030
The market for onchocerciasis treatments has experienced robust expansion recently, with projections indicating growth from $1.11 billion in 2025 to $1.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. This historical increase is largely driven by several key factors: the scarce supply of ivermectin and doxycycline in areas where the disease is prevalent, a heavy dependence on hospital-centered distribution networks, limited public understanding of how to manage the condition, insufficient implementation of preventive chemotherapy initiatives, and an exclusive reliance on oral medication formats.
The market for onchocerciasis treatments is anticipated to experience considerable expansion in the coming years, reaching $1.59 billion by 2030 with a compound annual growth rate of 7.4%. This projected growth during the forecast timeframe is driven by factors such as the launch of moxidectin and prolonged-release formulations, the widening availability through online and retail pharmacies, the creation of combination therapies, heightened government and NGO funding for eradication initiatives, and the establishment of community-focused preventive strategies. Key developments expected in the forecast period involve the scaling up of mass drug administration programs, the creation of pediatric and fixed-dose formulations, a rising emphasis on anti-Wolbachia therapies, the blending of oral and injectable treatment protocols, and the expansion of community-led and governmental treatment campaigns.
Download A Free Sample Report For Comprehensive Market Insights:
Onchocerciasis Treatment Market Expansion Supported By Key Demand Factors
The increasing number of individuals impacted by ocular conditions is anticipated to drive the expansion of the onchocerciasis treatment market in the coming period. Ocular conditions encompass a range of disorders affecting vision and eye health, such as infections, injuries, and long-term diseases like glaucoma or cataracts. This rise in affected patients is largely attributed to heightened screen usage and extended exposure to digital devices. Onchocerciasis treatment aids in averting and controlling vision impairment and blindness in individuals by eradicating the parasitic infection that induces inflammation and harm to eye tissues. By way of example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health body, reported that approximately 20.5 million Americans aged over 40 have cataracts in one eye, representing 17.2% of that demographic. It is estimated that nearly 30 million individuals will develop cataracts by 2028. Consequently, the growing frequency of eye-related disorders is fueling the onchocerciasis treatment market.
The growing need for surgical procedures is projected to stimulate the onchocerciasis treatment market’s growth moving forward. Surgical procedures are medical interventions designed to extract or fix tissues compromised by disease, frequently applied when pharmaceutical treatments are unsuccessful or when complications threaten lasting health. This escalation stems from the progression of onchocerciasis in certain patients to severe phases, where surgical action is needed to avoid permanent harm, like vision loss or deformity. In response, healthcare providers are broadening surgical offerings and investing in cutting-edge techniques, thereby enhancing the onchocerciasis treatment market. For instance, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional association for board-certified cosmetic plastic surgeons, indicated that in 2023, almost 35 million aesthetic procedures were carried out globally, a 3.4% rise from 2022. The report further noted that surgical interventions grew by 5.5%, with over 15.8 million procedures executed by plastic surgeons. Hence, the increasing demand for surgical procedures is driving expansion in the onchocerciasis treatment market.
Onchocerciasis Treatment Market Segment Analysis And Revenue Opportunities
The onchocerciasis treatment market covered in this report is segmented –
1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin
2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment
3) By Mode Of Administration: Oral, Injectables, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs
Subsegments:
1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations
2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments
3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas
4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs
Onchocerciasis Treatment Market Growth Trends Influencing Competitive Dynamics
Leading companies in the onchocerciasis treatment space are prioritizing the development of innovative antiparasitic drugs aimed at boosting therapeutic outcomes and shortening treatment timelines. These antiparasitic agents work by eradicating or suppressing parasites such as protozoa and worms that cause human infections. A notable example occurred in December 2024, when Medicines Development for Global Health (MDGH), an Australian nonprofit biopharmaceutical organization, secured approval from Ghana’s Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets. This medication is indicated for treating river blindness in patients aged 4 years and older. The clearance allows Ghana to initiate community-wide mass drug administration campaigns using moxidectin, which demonstrates enhanced effectiveness and prolonged action compared to ivermectin. Through this regulatory milestone, MDGH seeks to broaden availability of a potent new therapy for onchocerciasis, facilitating large-scale community-based interventions in endemic areas.
Onchocerciasis Treatment Market Leading Players Shaping Industry Direction
Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.
Access The Complete Onchocerciasis Treatment Market Report:
Onchocerciasis Treatment Market Geographic Distribution And Regional Opportunities
North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
